Tasly Pharmaceutical Group (600535.SH): Fumagillin FV Tab is granted a drug registration certificate.

Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tasly Pharmaceutical Group Diyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiangsu Diyi"), recently received the drug registration certificate for Fumaric acid furosemide tablets issued by the National Medical Products Administration. Fumaric acid furosemide tablets, an innovative drug, obtained market approval in Japan in December 2014 and in China in December 2019, with Takeda Pharmaceutical Company Limited as the holder of the license. This product is used for the treatment of reflux esophagitis, in combination with appropriate antibiotics to eradicate Helicobacter pylori. As of the date of this announcement, there are a total of 57 manufacturers in China, including Jiangsu Diyi, holding the registration certificate for Fumaric acid furosemide tablets.